Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP
Nexus Pharmaceuticals announces FDA approval of its Methylene Blue Injection, USP, for the treatment of acquired methemoglobinemia, reinforcing its commitment to delivering critical, life-saving medications.